Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BioAge Labs, Inc. due to alleged violations of federal securities laws related to misleading information about its STRIDES Phase 2 clinical trial [2][4]. Group 1: Company Overview - BioAge Labs, Inc. (NASDAQ: BIOA) completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, including an additional 1.65 million shares purchased by underwriters [4]. - The company faced significant stock price decline following the announcement on December 6, 2024, that it would discontinue the STRIDES Phase 2 study of its drug candidate azelaprag due to liver transaminitis observed in subjects [5][6]. Group 2: Legal Proceedings - A federal securities class action has been filed against BioAge, with a deadline of March 10, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [7]. Group 3: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in BioAge to contact them directly to discuss legal options [1][8]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding BioAge's conduct [8].
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs